FKGK11
FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2) . FKGK11 can be used for the research of ovarian cancer and neurological disorders such as peripheral nerve injury and multiple sclerosis[1][2].
Product Specifications
CAS Number
1071000-98-0
UNSPSC
12352005
Target
Phospholipase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/fkgk11.html
Concentration
17.84 mM * 200 μL in Ethanol
Purity
99.00
Solubility
10 mM in DMSO
Smiles
O=C(C(F)(C(F)(F)F)F)CCCCC1=CC=CC=C1
Molecular Formula
C13H13F5O
Molecular Weight
280.23
References & Citations
[1]Kokotos G, et al. Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53 (9) :3602-10.|[2]Yan Xu, et al. Abstract 3525: Targeting Group VIA phospholipase A2 using small molecules for ovarian cancer treatment. Cancer Res (2011) 71 (8_Supplement) : 3525.|[3]López-Vales R, et al. Intracellular phospholipase A (2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury. Brain. 2008 Oct;131 (Pt 10) :2620-31.
Shipping Conditions
Blue Ice
Storage Conditions
Solution, -20°C, 2 years
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Phospholipase A
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY400125 100 µg
delta Sarcoglycan (SGCD) (NM_000337) Human Over-expression Lysate
Sign In for Pricing
View Details